Talphera Inc. (TLPH) - Total Assets
Based on the latest financial reports, Talphera Inc. (TLPH) holds total assets worth $29.72 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Talphera Inc. debt service capacity to assess how comfortably operating cash covers total debt obligations.
Talphera Inc. - Total Assets Trend (2008–2025)
This chart illustrates how Talphera Inc.'s total assets have evolved over time, based on quarterly financial data. See what is Talphera Inc.'s book value for net asset value and shareholders' equity analysis.
Talphera Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Talphera Inc.'s total assets of $29.72 Million consist of 70.3% current assets and 29.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $8.82 Million | 29.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Talphera Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Talphera Inc. stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Talphera Inc.'s current assets represent 70.3% of total assets in 2025, a decrease from 92.5% in 2008.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2025, down from 26.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 29.7% of total assets.
Talphera Inc. Competitors by Total Assets
Key competitors of Talphera Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Talphera Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.49 | 3.56 | 4.59 |
| Quick Ratio | 5.49 | 3.56 | 4.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.09 Million | $6.77 Million | $55.77 Million |
Talphera Inc. - Advanced Valuation Insights
This section examines the relationship between Talphera Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.73 |
| Latest Market Cap to Assets Ratio | 1.58 |
| Asset Growth Rate (YoY) | 63.0% |
| Total Assets | $29.72 Million |
| Market Capitalization | $46.90 Million USD |
Valuation Analysis
Above Book Valuation: The market values Talphera Inc.'s assets above their book value (1.58x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Talphera Inc.'s assets grew by 63.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Talphera Inc. (2008–2025)
The table below shows the annual total assets of Talphera Inc. from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.72 Million | +62.97% |
| 2024-12-31 | $18.24 Million | -10.59% |
| 2023-12-31 | $20.39 Million | -57.05% |
| 2022-12-31 | $47.49 Million | -39.04% |
| 2021-12-31 | $77.89 Million | +17.49% |
| 2020-12-31 | $66.30 Million | -27.43% |
| 2019-12-31 | $91.36 Million | -24.21% |
| 2018-12-31 | $120.53 Million | +59.54% |
| 2017-12-31 | $75.55 Million | -24.44% |
| 2016-12-31 | $99.99 Million | -21.75% |
| 2015-12-31 | $127.78 Million | +47.87% |
| 2014-12-31 | $86.42 Million | -21.46% |
| 2013-12-31 | $110.03 Million | +70.54% |
| 2012-12-31 | $64.52 Million | +58.00% |
| 2011-12-31 | $40.84 Million | +497.88% |
| 2010-12-31 | $6.83 Million | -52.87% |
| 2009-12-31 | $14.49 Million | -36.10% |
| 2008-12-31 | $22.68 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more